Johnson & Johnson initiated with an Outperform at Wolfe Research
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson with an Outperform rating and $190 price target ...
Business Insider22h
Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study
Johnson & Johnson announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% ...
Benzinga.com1d
Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs
Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the plan ...
MassDevice2d
Johnson & Johnson wins FDA IDE for Ottava surgical robot
Johnson & Johnson MedTech announced today that the FDA granted its Ottava surgical robot investigational device exemption ...
Johnson & Johnson: Tracking Well Above The Industry
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
Becker's Spine Review11h
Johnson & Johnson MedTech inks distribution deal with Responsive Arthroscopy
Johnson & Johnson MedTech has entered into an exclusive commercial distribution agreement with Responsive Arthroscopy, a medical device company specializing in sports soft tissue repair solutions. The ...
Johnson & Johnson Told to Pay $15 Million to Man Who Says Its Talc Caused His Cancer
Johnson & Johnson has been ordered to pay $15 million to a Connecticut man who claimed he developed mesothelioma, a rare form ...
Crain's Detroit9d
Johnson & Johnson backs UM spinout in $65M funding round
ONL Therapeutics Inc. is a classic case of a University of Michigan spinout. The Ann Arbor biotechnology startup netted the largest VC deal in the state in Q3, closing an oversubscribed $65 million ...